Despite widespread reports last month that a drug approved to fight osteoporosis also decreases the risk of breast cancer among post-menopausal women, a federal judge has enjoined the drug’s manufacturer from promoting the drug as protecting against cancer.

U.S. District Judge John G. Koeltl in Zeneca Inc. v. Eli Lilly and Co., 99-Civ.-1452 (QDS:02310323), last Thursday granted a preliminary injunction against drug maker Eli Lilly and Co.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]